<DOC>
	<DOCNO>NCT00138593</DOCNO>
	<brief_summary>This study conduct United States . This 52-week extension study assess safety effectiveness two dos vildagliptin , unapproved drug , lower overall blood glucose level people type 2 diabetes previously treat drug therapy lower blood sugar whose blood sugar level specify range . The purpose extension study gather data long term safety effectiveness vildagliptin people type 2 diabetes .</brief_summary>
	<brief_title>Extension Study Efficacy Safety Vildagliptin Patients With Type 2 Diabetes With Hemoglobin A1c ( HbA1c ) 9-11 %</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Vildagliptin</mesh_term>
	<criteria>Only patient successfully complete study CLAF237A2329 eligible Written inform consent HbA1c reduction baseline week 12 ( visit 5 ) core study great equal 0.3 absolute unit Ability comply study requirement Premature discontinuation study CLAF237A2329 Other protocoldefined exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Type 2 diabetes</keyword>
	<keyword>vildagliptin</keyword>
</DOC>